RINVOQ Abbvie Pty Ltd
Product name
RINVOQ
Sponsor
Accepted date
Dec-2025
Active ingredients
upadacitinib hemihydrate
Proposed indication
RINVOQ (upadacitinib hemihydrate) is proposed to treat children and adults aged 2 years and older who have active polyarticular juvenile idiopathic arthritis. It can be taken on its own or together with methotrexate.
Application type
C (new indication)
Publication date
Dec-2025